| Dr John S Schor, MD | |
|
294 W State Route 89a, Suite 107, Cottonwood, AZ 86326-3754 | |
| (928) 634-1331 | |
| (928) 634-3130 |
| Full Name | Dr John S Schor |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 37 Years |
| Location | 294 W State Route 89a, Cottonwood, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568459717 | NPI | - | NPPES |
| 131591 | Medicaid | AZ |
| Facility Name | Location | Facility Type |
|---|---|---|
| Verde Valley Medical Center | Cottonwood, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Arizona Healthcare Corporation | 3577473362 | 370 |
News Archive
Split liver transplantation (SLT) provides an opportunity to divide a donor liver and offer transplants to two small patients, one or both of whom could be a child. SLT, which is underused in the United States, could be used more widely to decrease the number of deaths of people on transplant waiting lists.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
Sanofi Pasteur announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.
› Verified 2 days ago
| Entity Name | Flagstaff Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780635078 PECOS PAC ID: 2769392554 Enrollment ID: O20031230000199 |
News Archive
Split liver transplantation (SLT) provides an opportunity to divide a donor liver and offer transplants to two small patients, one or both of whom could be a child. SLT, which is underused in the United States, could be used more widely to decrease the number of deaths of people on transplant waiting lists.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
Sanofi Pasteur announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.
› Verified 2 days ago
| Entity Name | Verde Valley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346291648 PECOS PAC ID: 7719898204 Enrollment ID: O20040202000833 |
News Archive
Split liver transplantation (SLT) provides an opportunity to divide a donor liver and offer transplants to two small patients, one or both of whom could be a child. SLT, which is underused in the United States, could be used more widely to decrease the number of deaths of people on transplant waiting lists.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
Sanofi Pasteur announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.
› Verified 2 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
Split liver transplantation (SLT) provides an opportunity to divide a donor liver and offer transplants to two small patients, one or both of whom could be a child. SLT, which is underused in the United States, could be used more widely to decrease the number of deaths of people on transplant waiting lists.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
Sanofi Pasteur announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John S Schor, MD 1200 N Beaver St, Payer Credentialing, Flagstaff, AZ 86001-3118 Ph: (928) 773-2559 | Dr John S Schor, MD 294 W State Route 89a, Suite 107, Cottonwood, AZ 86326-3754 Ph: (928) 634-1331 |
News Archive
Split liver transplantation (SLT) provides an opportunity to divide a donor liver and offer transplants to two small patients, one or both of whom could be a child. SLT, which is underused in the United States, could be used more widely to decrease the number of deaths of people on transplant waiting lists.
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.
An experimental microbicide containing a naturally occurring compound provides protection in monkeys against the simian version of HIV by diminishing immune responses to the virus, according to a study published Wednesday in the journal Nature, the Los Angeles Times reports.
Sanofi Pasteur announced today it has received the first of what is expected to be a series of orders from the U.S. Department of Health and Human Services (HHS) to commence production of a vaccine to help protect against the new influenza A(H1N1) virus.
› Verified 2 days ago